Tumor-informed assessment of molecular residual disease
Kasi PM, Dayyani F, Morris V. Poster presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4108.
Read Flipbook
Kasi PM, Dayyani F, Morris V. Poster presentation at: American Society of Clinical Oncologist; May 29-31, 2020; Virtual Meeting. Abstract 4108.
Read Flipbook
Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response and/or detect disease recurrence earlier.
Read Flipbook
Studies on different cancer types have shown that circulating tumor DNA (ctDNA) levels can be efficiently used to monitor treatment response to neoadjuvant therapy.
Read Flipbook
Circulating tumor DNA (ctDNA) has emerged as a promising, non-invasive biomarker for preclinical detection and monitoring of various cancers.
Read Flipbook
Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).
Read Flipbook
Read Flipbook
Hook N, Wallace J, Zimmermann B, et al. Poster presented at: 2020 European Society of Human Genetics; June 6-9, 2020. Abstract E-P16.04.
Read Flipbook
The identification of tumor mutations in circulating cell-free DNA (cfDNA) holds great potential for the noninvasive detection of cancer relapse.
Read Flipbook
Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for early prediction of relapse across different tumor types.
Read Flipbook
Early detection of disease recurrence has been shown to improve survival in patients with colorectal cancer (CRC); detection of circulating tumor DNA (ctDNA).
Read Flipbook
Analysis of circulating tumor DNA (ctDNA) offers a minimally invasive approach for monitoring treatment response and resistance to treatment in patients with breast cancer.
Read Flipbook
The potential utility of circulating tumor DNA (ctDNA) to detect minimal residual disease (MRD) following surgery and/or adjuvant therapy and to monitor metastatic disease has been demonstrated.
Read Flipbook
The advent of ultra-sensitive and specific molecular assays has increased the feasibility of circulating tumor DNA (ctDNA) detection.
Read Flipbook
Epithelial ovarian, fallopian tube, and peritoneal cancer (EOC) is the most lethal gynecologic malignancy with a 5-year survival rate of 47%.
Read Flipbook
Two metrics are commonly used to quantify tumor-specific variants in cell-free DNA (cfDNA): the variant allele frequency (VAF) and mean tumor molecules (MTM)/mL of plasma.
Read Flipbook